Telescope InnovationsTELIF -2.86%27 Return-on-Tangible-Equity is -137.47% as of May. 2026. GuruFocus rates TELIF with a GF Score™ of 27/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,195 Biotechnology companies, Telescope Innovations ranks worse than 78.41% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Telescope Innovations's annualized net income for the quarter that ended in May. 2026 was $-4.10 Mil. Telescope Innovations's average shareholder tangible equity for the quarter that ended in May. 2026 was $2.98 Mil. Therefore, Telescope Innovations's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2026 was -137.47%.
The historical rank and industry rank for Telescope Innovations's Return-on-Tangible-Equity or its related term are showing as below:
TELIF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -224.67 Med: -88.76 Max: -33.79
Current: -126.02
During the past 7 years, Telescope Innovations's highest Return-on-Tangible-Equity was -33.79%. The lowest was -224.67%. And the median was -88.76%.
TELIF's Return-on-Tangible-Equity is ranked worse than 78.41% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs TELIF: -126.02
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Telescope Innovations Return-on-Tangible-Equity Related Terms
Telescope Innovations Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Telescope Innovations's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (May. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -137.47% mean?
Telescope Innovations (TELIF) has a Return-on-Tangible-Equity of -137.47% as of May. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Telescope Innovations and its competitors. According to the industry distribution chart, Telescope Innovations ranks #937 out of 1195 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Telescope Innovations' Return-on-Tangible-Equity too high?
Telescope Innovations' current Return-on-Tangible-Equity is -137.47%. Based on the distribution chart, Telescope Innovations ranks #937 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telescope Innovations has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #937 out of 1195 companies for Return-on-Tangible-Equity. This places Telescope Innovations in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Telescope Innovations and its competitors. Telescope Innovations's current Return-on-Tangible-Equity is -137.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.51 — trading 34.2% above its estimated fair value. The current Return-on-Tangible-Equity is -137.47%. Telescope Innovations' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current Return-on-Tangible-Equity is -137.47% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.51 is trading 34.2% above its estimated GF Value™ of $0.38.
GuruFocus considers Telescope Innovations to be Significantly Overvalued.
Key valuation signals for TELIF:
Return-on-Tangible-Equity: -137.47%
GF Value™: $0.38 vs. price of $0.51 (34.2% above fair value)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
27GF Score
Get the complete analysis for TELIF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
